Viloxazine for Attention-Deficit Hyperactivity Disorder: A Systematic Review and Meta-analysis of Randomized Clinical Trials

BACKGROUND: Recently, the United States Food and Drug Administration (USFDA) approved viloxazine extended-release (ER) to manage attention-deficit hyperactivity disorder (ADHD) in pediatric patients of 6–17 years of age. OBJECTIVE: To perform a meta-analysis to determine the safety and efficacy of v...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Alok, Balasundaram, Mahesh Kumar, Singh, Abhishek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9125110/
https://www.ncbi.nlm.nih.gov/pubmed/35615643
http://dx.doi.org/10.1177/11795735221092522

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9125110/
https://www.ncbi.nlm.nih.gov/pubmed/35615643
http://dx.doi.org/10.1177/11795735221092522

Ejemplares similares